A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Saved in:
| Title: | A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. |
|---|---|
| Authors: | Lu G; Portola Pharmaceuticals, Inc., South San Francisco, CA., Conley PB; Portola Pharmaceuticals, Inc., South San Francisco, CA., Leeds JM; Portola Pharmaceuticals, Inc., South San Francisco, CA., Karbarz MJ; Portola Pharmaceuticals, Inc., South San Francisco, CA., Levy GG; Portola Pharmaceuticals, Inc., South San Francisco, CA., Mathur VS; Mathur Consulting, San Francisco, CA; and., Castillo J; Portola Pharmaceuticals, Inc., South San Francisco, CA., Crowther M; Department of Medicine, McMaster University, Hamilton, ON, Canada., Curnutte JT; Portola Pharmaceuticals, Inc., South San Francisco, CA. |
| Source: | Blood advances [Blood Adv] 2020 Feb 25; Vol. 4 (4), pp. 728-739. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2473-9537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2019000885 |
